文献速递白血病

急性髓系白血病治疗过程中TP53突变的新发获得

Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2021-08-19

该回顾性研究纳入200例初诊TP53野生型AML患者,分析其复发或难治时新发可检测TP53突变的情况。结果显示15%的患者在新发TP53突变,中位VAF为15%,且高强度治疗和造血干细胞移植后更常见;TP53 VAF≥20%与更差的总生存显著相关。

要点

  • 初诊TP53野生型AML患者中,15%在复发/难治时新发TP53突变。
  • 高强度治疗及造血干细胞移植后新发TP53突变更常见。
  • TP53 VAF≥20%与更低的CR/CRi率和更短OS显著相关。

核心结论

  • 新发TP53突变可在AML治疗全过程中获得。
  • TP53 VAF≥20%与更差的总生存显著相关(中位OS 3.5个月 vs 6.1个月,p<0.05)。

研究设计与样本

  • 回顾性分析200例初诊TP53野生型AML患者,均为前线治疗后复发或难治。

主要发现

  • 高强度治疗 vs 低强度治疗后新发TP53突变比例为23% vs 10%(p=0.02)。
  • 造血干细胞移植 vs 未移植后新发TP53突变比例为36% vs 12%(p=0.005)。
  • TP53 VAF<20% vs ≥20%的CR/CRi率分别为41% vs 13%。
  • 获得TP53突变后中位OS为4.6个月,1年OS率为19%。

关键数值与推荐

  • TP53 VAF≥20%患者中位OS为3.5个月,VAF<20%患者为6.1个月(p<0.05)。
  • TP53 VAF<20%患者CR/CRi率为41%,VAF≥20%患者为13%。

临床怎么用

  • 对复发/难治AML患者应考虑序贯监测TP53突变。
  • 新发TP53突变时,TP53 VAF水平可用于预后分层。

局限性

  • 回顾性研究设计。
  • 新发TP53突变的发生率及预后影响需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TP53 mutations in acute myeloid leukemia (AML) are associated with resistance to standard treatments and dismal outcomes. The incidence and prognostic impact of the emergence of newly detectable TP53 mutations over the course of AML therapy has not been well described. We retrospectively analyzed 200 patients with newly diagnosed TP53 wild type AML who relapsed after or were refractory to frontline therapy. Twenty-nine patients (15%) developed a newly detectable TP53 mutation in the context of relapsed/refractory disease. The median variant allelic frequency (VAF) was 15% (range, 1.1%-95.6%). TP53 mutations were more common after intensive therapy versus lower-intensity therapy (23% vs. 10%, respectively; p = 0.02) and in patients who had undergone hematopoietic stem cell transplant versus those who had not (36% vs. 12%, respectively; p = 0.005). Lower TP53 VAF was associated with an increased likelihood of complete remission (CR) or CR with incomplete hematologic recovery (CRi) compared to higher TP53 VAF (CR/CRi rate of 41% for VAF < 20% vs. 13% for VAF ≥ 20%, respectively). The median overall survival (OS) after acquisition of TP53 mutation was 4.6 months, with a 1-year OS rate of 19%. TP53 VAF at relapse was significantly associated with OS; the median OS of patients with TP53 VAF ≥ 20% was 3.5 months versus 6.1 months for those with TP53 VAF < 20% (p < 0.05). In summary, new TP53 mutations may be acquired throughout the course of AML therapy. Sequential monitoring for TP53 mutations is likely to be increasingly relevant in the era of emerging TP53-targeting therapies for AML.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Alwash Y, Khoury JD, Tashakori M, et al. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021. PMID: 34351647. doi:10.1002/ajh.26314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。